{"id":"https://openalex.org/W4380029577","doi":"https://doi.org/10.1158/1538-7445.am2023-6300","title":"Abstract 6300: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers","display_name":"Abstract 6300: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers","alternate_titles":[],"publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4380029577","doi":"https://doi.org/10.1158/1538-7445.am2023-6300"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2023-6300","doi":"https://doi.org/10.1158/1538-7445.am2023-6300","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-6300","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4380029577"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Mo Dan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387153926","display_name":"CSPC Pharmaceutical Group","ror":"https://ror.org/016mq8947","country_code":"CN","type":"company","lineage":["https://openalex.org/I4387153926"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Mo Dan","raw_affiliation_strings":["1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;","institution_ids":["https://openalex.org/I4387153926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081831611","display_name":"Xiwu Hui","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387153926","display_name":"CSPC Pharmaceutical Group","ror":"https://ror.org/016mq8947","country_code":"CN","type":"company","lineage":["https://openalex.org/I4387153926"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xiwu Hui","raw_affiliation_strings":["2CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China;","institution_ids":["https://openalex.org/I4387153926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024533730","display_name":"Yancui Wang","orcid":"https://orcid.org/0000-0002-3436-2355","observed_orcids":["https://orcid.org/0000-0002-3436-2355"]},"institutions":[{"id":"https://openalex.org/I4387153926","display_name":"CSPC Pharmaceutical Group","ror":"https://ror.org/016mq8947","country_code":"CN","type":"company","lineage":["https://openalex.org/I4387153926"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yancui Wang","raw_affiliation_strings":["1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;","institution_ids":["https://openalex.org/I4387153926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102195529","display_name":"Can Yuan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387153926","display_name":"CSPC Pharmaceutical Group","ror":"https://ror.org/016mq8947","country_code":"CN","type":"company","lineage":["https://openalex.org/I4387153926"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Can Yuan","raw_affiliation_strings":["2CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China;","institution_ids":["https://openalex.org/I4387153926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113140138","display_name":"Thomas O\u2019Hare","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas O'Hare","raw_affiliation_strings":["3Elevation Oncology, Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Elevation Oncology, Inc., New York, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048549140","display_name":"Valerie Malyvanh Jansen","orcid":"https://orcid.org/0009-0002-5754-6111","observed_orcids":["https://orcid.org/0009-0002-5754-6111"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Valerie Malyvanh Jansen","raw_affiliation_strings":["3Elevation Oncology, Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Elevation Oncology, Inc., New York, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046337695","display_name":"Shawn Michael Leland","orcid":"https://orcid.org/0000-0002-8943-204X","observed_orcids":["https://orcid.org/0000-0002-8943-204X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shawn M. Leland","raw_affiliation_strings":["3Elevation Oncology, Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Elevation Oncology, Inc., New York, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100354681","display_name":"Yang Zhang","orcid":"https://orcid.org/0000-0002-4061-4408","observed_orcids":["https://orcid.org/0000-0002-4061-4408","https://orcid.org/0000-0002-0033-1833"]},"institutions":[{"id":"https://openalex.org/I4387153926","display_name":"CSPC Pharmaceutical Group","ror":"https://ror.org/016mq8947","country_code":"CN","type":"company","lineage":["https://openalex.org/I4387153926"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yang Zhang","raw_affiliation_strings":["1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;","institution_ids":["https://openalex.org/I4387153926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022628721","display_name":"David Dornan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Dornan","raw_affiliation_strings":["3Elevation Oncology, Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Elevation Oncology, Inc., New York, NY","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088352039","display_name":"X.Y. Wang","orcid":"https://orcid.org/0000-0002-4736-216X","observed_orcids":["https://orcid.org/0000-0002-4736-216X"]},"institutions":[{"id":"https://openalex.org/I4387153926","display_name":"CSPC Pharmaceutical Group","ror":"https://ror.org/016mq8947","country_code":"CN","type":"company","lineage":["https://openalex.org/I4387153926"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xiaoyan Wang","raw_affiliation_strings":["1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China;","institution_ids":["https://openalex.org/I4387153926"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"7_Supplement","first_page":"6300","last_page":"6300"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8838000297546387,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8838000297546387,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.015399999916553497,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.014399999752640724,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8550000190734863},{"id":"https://openalex.org/keywords/claudin-18-2","display_name":"claudin 18.2","score":0.8820000290870667},{"id":"https://openalex.org/keywords/monomethyl-auristatin-e","display_name":"monomethyl auristatin E","score":0.9290000200271606},{"id":"https://openalex.org/keywords/cleavable-linkers","display_name":"cleavable linkers","score":0.7120000123977661},{"id":"https://openalex.org/keywords/drug-to-antibody-ratio","display_name":"drug-to-antibody ratio","score":0.7839999794960022},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.7689999938011169},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.628000020980835},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.6959999799728394},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.8119999766349792},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6449999809265137}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4934488832950592},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.4886189103126526},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45787331461906433},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.4574820399284363},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.39899951219558716},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38592326641082764},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.34095072746276855},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.26872116327285767},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.26831769943237305},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.238160640001297},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.13516831398010254},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12336790561676025},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09913498163223267}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2023-6300","doi":"https://doi.org/10.1158/1538-7445.am2023-6300","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-6300","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4380146456","https://openalex.org/W4391091318","https://openalex.org/W4282978458","https://openalex.org/W3181651719","https://openalex.org/W4323570105","https://openalex.org/W4387312340","https://openalex.org/W4393095078","https://openalex.org/W4307909027","https://openalex.org/W7148771602","https://openalex.org/W4282979504"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Claudin18.2":[2,399],"(CLDN18.2),":[3],"a":[4,53,60,69,73,260,398],"tight":[5],"junction":[6],"protein":[7],"normally":[8],"expressed":[9],"only":[10],"on":[11,33,145,155,208],"gastric":[12,182,277],"mucosa,":[13],"is":[14,31,347],"overexpressed":[15],"in":[16,27,36,181,269,302,309,316,325,328,361],"gastric,":[17,317],"pancreatic,":[18,318],"esophageal,":[19],"ovarian,":[20],"lung":[21,189,281,320],"and":[22,89,109,118,154,175,188,202,215,236,238,248,266,280,293,313,319,327,355,424],"other":[23],"solid":[24,367],"tumors.":[25],"Unlike":[26],"normal":[28],"tissue,":[29],"CLDN18.2":[30,58,153,163,209,250,364],"exposed":[32],"epithelial":[34],"surfaces":[35],"malignancy.":[37],"There":[38],"are":[39],"no":[40],"approved":[41],"targeted":[42],"therapies":[43],"for":[44,338,402,415],"CLDN18.2-expressing":[45,84,268,341,406],"cancers.":[46,342],"An":[47],"antibody-drug":[48,400],"conjugate":[49],"(ADC)":[50],"composed":[51],"of":[52,77,107,139,204,224,289,336,359,396,405,411],"monoclonal":[54],"antibody":[55,110],"(mAb)":[56],"targeting":[57],"with":[59,130,158,245,259,340,363],"monomethyl":[61],"auristatin":[62],"E":[63],"(MMAE)":[64],"payload":[65,104],"site-specifically":[66],"conjugated":[67],"via":[68],"cleavable":[70],"linker":[71],"at":[72],"drug-antibody":[74],"ratio":[75],"(DAR)":[76],"2,":[78],"EO-3021/SYSA1801,":[79,397],"was":[80,143],"developed":[81],"to":[82,98,151,161,196,349],"target":[83],"cancer":[85,191,197,321],"cells,":[86,198],"minimize":[87],"toxicities":[88],"maximize":[90],"therapeutic":[91,334],"index.":[92],"Methods:":[93],"HEK293-CLDN18.2":[94],"cells":[95,129],"were":[96,121,179,206],"used":[97],"evaluate":[99,350],"CLDN18.2-dependent":[100],"EO-3021":[101,131,136,142,194,211,216,226,229,255,294,306],"endocytosis,":[102,199],"MMAE":[103,200],"release,":[105,201],"inhibition":[106,170,203],"proliferation":[108,140,205],"dependent":[111,207],"cellular":[112],"cytotoxicity":[113],"(ADCC).":[114],"Cell":[115],"cycle":[116,234],"distribution":[117],"caspase-3/7":[119],"activity":[120,241,312,358],"measured":[122,144],"24":[123],"hours":[124],"after":[125],"treating":[126],"BxPC3-CLDN18.2":[127],"pancreatic":[128,185,274],"or":[132,177],"the":[133,332,351,403,412],"unconjugated":[134],"antibody,":[135],"mAb.":[137],"Inhibition":[138],"by":[141,171],"cell":[146,156,233,243],"lines":[147,157,244],"ectopically":[148],"expressing":[149],"medium":[150,162],"high":[152,249,267],"endogenous":[159],"low":[160],"expression.":[164,210],"Xenograft":[165],"studies":[166,330],"evaluating":[167],"tumor":[168,257,299],"growth":[169],"EO-3021,":[172],"EO3021":[173],"mAb,":[174],"cisplatin":[176],"gemcitabine":[178],"done":[180],"(NUGC4;":[183],"NUGC4-CLDN18.2),":[184],"(Patu8988S;":[186],"BxPC3-CLDN18.2),":[187],"(NCI-H460)":[190],"models.":[192,304,322],"Results:":[193],"binding":[195],"(EC50:":[212,218],"172":[213],"ng/ml)":[214,220],"mAb":[217,230,295],"130":[219],"demonstrated":[221,307],"similar":[222],"levels":[223],"ADCC.":[225],"but":[227],"not":[228,297],"promoted":[231],"G2/M":[232],"arrest":[235],"apoptosis":[237],"exhibited":[239],"potent":[240],"across":[242,263,301],"low,":[246,264],"medium,":[247,265],"expression":[251],"(IC50:":[252],"7-456":[253],"ng/mL).":[254],"induced":[256],"regressions":[258,300],"single":[261],"dose":[262],"vivo":[270,303,310,329],"models":[271],"derived":[272],"from":[273,324],"(2-10":[275],"mg/kg),":[276,279,284],"(0.5-10":[278],"cancers":[282,407],"(4":[283],"respectively.":[285],"In":[286],"contrast,":[287],"standard":[288],"care":[290],"(SOC)":[291],"chemotherapies":[292],"did":[296],"induce":[298],"Conclusions:":[305],"profound":[308],"antitumor":[311],"outperformed":[314],"SOC":[315],"Results":[323],"vitro":[326],"highlight":[331],"promising":[333],"potential":[335,395],"EO-3021/SYSA1801":[337],"patients":[339,362],"A":[343],"Phase":[344],"1":[345,422],"study":[346],"ongoing":[348],"safety,":[352],"tolerability,":[353],"pharmacokinetics":[354],"preliminary":[356],"anti-tumor":[357],"SYSA1801":[360],"positive":[365],"advanced":[366],"tumors":[368],"(NCT05009966).":[369],"Citation":[370],"Format:":[371],"Mo":[372],"Dan,":[373],"Xiwu":[374],"Hui,":[375],"Yancui":[376],"Wang,":[377],"Can":[378],"Yuan,":[379],"Thomas":[380],"O'Hare,":[381],"Valerie":[382],"Malyvanh":[383],"Jansen,":[384],"Shawn":[385],"M.":[386],"Leland,":[387],"Yang":[388],"Zhang,":[389],"David":[390],"Dornan,":[391],"Xiaoyan":[392],"Wang.":[393],"Therapeutic":[394],"conjugate,":[401],"treatment":[404],"[abstract].":[408],"In:":[409],"Proceedings":[410],"American":[413],"Association":[414],"Cancer":[416,435],"Research":[417],"Annual":[418],"Meeting":[419],"2023;":[420],"Part":[421],"(Regular":[423],"Invited":[425],"Abstracts);":[426],"2023":[427],"Apr":[428],"14-19;":[429],"Orlando,":[430],"FL.":[431],"Philadelphia":[432],"(PA):":[433],"AACR;":[434],"Res":[436],"2023;83(7_Suppl):Abstract":[437],"nr":[438],"6300.":[439]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4380029577","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-06-10T00:00:00"}
